22
7
6
4
4
1
22
7
6
4
4
1
The Greene Climacteric Scale is a validated, self-report questionnaire developed by Dr. John Greene in 1976 and revised in 1998, designed to comprehensively assess the range and severity of menopausal symptoms. It is one of the most widely used instruments in climacteric research and clinical practice, recognized for its robust psychometric properties and its ability to capture the multidimensional nature of menopausal complaints.
The scale consists of 21 items organized into five symptom subscales: psychological anxiety (6 items), psychological depression (6 items), somatic symptoms (7 items), vasomotor symptoms (2 items), and sexual function (1 item). Each item is rated on a 4-point Likert scale from 0 (not at all) to 3 (extremely), based on the patient's experience over the preceding weeks. The total possible score ranges from 0 to 63, with higher scores indicating greater symptom burden.
The development of the Greene Climacteric Scale was grounded in factor analysis of menopausal symptom patterns, which identified distinct psychological, somatic, and vasomotor dimensions. This evidence-based structure differentiates it from earlier indices like the Blatt-Kupperman Index, which used arbitrary weighting systems. The Greene Scale's subscale structure allows clinicians to identify which symptom domains are most affected, enabling more targeted therapeutic interventions.
The psychological anxiety subscale encompasses symptoms such as feeling tense, difficulty sleeping, excitability, panic attacks, heart pounding, and difficulty concentrating. The depression subscale captures fatigue, loss of interest, unhappiness, crying spells, irritability, and dizziness. The somatic subscale addresses physical symptoms including headaches, muscle and joint pains, numbness, breathing difficulties, and pressure in the head. The vasomotor subscale specifically addresses hot flashes and night sweats, while the sexual function subscale evaluates loss of libido.
Clinical applications of the Greene Climacteric Scale include baseline assessment of menopausal symptom severity, monitoring treatment response over time, comparing the efficacy of different therapeutic interventions in clinical trials, and screening for domains that may benefit from specialized referral (such as psychological symptoms warranting mental health evaluation). The scale has been translated into over 20 languages and validated across diverse cultural settings.
Normative data suggests that mean total scores during the menopausal transition range from 15 to 25, with vasomotor symptoms peaking in the early postmenopause and psychological symptoms often preceding the final menstrual period. Scores above 30 generally indicate significant symptom burden warranting active intervention. The scale's sensitivity to change makes it particularly useful for tracking therapeutic outcomes.
This calculator automates the scoring of the complete 21-item Greene Climacteric Scale, providing the total score and all five subscale scores. It enables rapid clinical assessment and longitudinal tracking of menopausal symptom patterns, supporting evidence-based management of the climacteric transition.
The 21 items are rated 0-3 and grouped into five subscales: Anxiety (items 1-6, max 18), Depression (items 7-12, max 18), Somatic (items 13-19, max 21), Vasomotor (items 19-20, max 6), and Sexual Function (item 21, max 3). Subscale and total scores are summed directly without weighting. The total score ranges from 0 to 63.
Higher scores indicate greater symptom severity. A total score above 30 suggests significant menopausal symptom burden. Subscale scores help identify dominant symptom domains. High anxiety or depression subscale scores may warrant psychological evaluation. High vasomotor scores are the strongest indication for hormone therapy. Track scores over time to assess treatment response.
Inputs
Results
Total score 22 indicates moderate symptoms with predominant anxiety and vasomotor components.
Inputs
Results
Lower total score but maximum vasomotor subscale indicates targeted hormone therapy may be beneficial.
The Greene Climacteric Scale is a validated 21-item questionnaire that measures menopausal symptom severity across five domains: anxiety, depression, somatic symptoms, vasomotor symptoms, and sexual function. It was developed by Dr. John Greene and is widely used in clinical practice and research.
The Greene Scale uses unweighted scoring based on factor analysis, includes sexual function, has more items, and provides distinct subscale scores. The Kupperman Index uses arbitrary symptom weighting and does not separate anxiety from depression or include sexual function.
Total scores above 30 out of 63 generally indicate significant menopausal symptom burden warranting active management. Mean scores during the menopausal transition typically range from 15 to 25. However, subscale patterns may be more clinically informative than the total score alone.
Baseline assessment should be followed by repeat evaluations every 3-6 months during treatment or transition. The scale is sensitive to treatment-induced changes, making it useful for monitoring therapy effectiveness over time.
The subscale structure helps differentiate menopausal symptoms from other conditions. High vasomotor scores are specific to menopause, while isolated high anxiety or depression scores may indicate primary psychiatric conditions requiring separate evaluation.
Yes. The Greene Climacteric Scale has been extensively validated with strong internal consistency (Cronbach alpha 0.83-0.87), test-retest reliability, and construct validity. It has been translated into over 20 languages with cross-cultural validation.
Hormone replacement therapy typically reduces total scores by 50-70%, particularly vasomotor and somatic subscales. SSRIs improve anxiety and depression subscales. Cognitive behavioral therapy helps psychological subscales. Exercise benefits all domains.
Yes. The scale is applicable to all forms of menopause including premature ovarian insufficiency, surgical menopause, and chemotherapy-induced menopause. Women with premature or surgical menopause often score higher due to more abrupt hormone withdrawal.
The single sexual function item measures loss of interest in sex (libido). While limited, it provides a basic screen for sexual dysfunction, which affects 40-50% of menopausal women. More detailed sexual function assessment may require additional instruments.
The scale was designed and validated for women experiencing menopause. While some items overlap with andropause symptoms, specific scales for male hypogonadism (such as the Aging Males' Symptoms scale) are more appropriate for men.
Roboculator Team
The Roboculator Team explains calculations, planning tools, and practical formulas in clear language for real-life situations.
How helpful was this calculator?
5.0/5 (1 rating)
